23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and
23ME-00610, an anti-CD200R1 antibody, shows preliminary clinical benefit in clear-cell renal-cell carcinoma with one confirmed partial response. Higher CD200 tumor expression and human genetics correlate with increased clinical benefit, suggesting potential as patient selection biomarkers. Greater response in 'cold' tumors indicates opportunity for patients unresponsive to PD-1/PD-L1 inhibitors.
Related Clinical Trials
Reference News
23ME-00610, an anti-CD200R1 antibody, shows preliminary clinical benefit in clear-cell renal-cell carcinoma with one confirmed partial response. Higher CD200 tumor expression and human genetics correlate with increased clinical benefit, suggesting potential as patient selection biomarkers. Greater response in 'cold' tumors indicates opportunity for patients unresponsive to PD-1/PD-L1 inhibitors.
23ME-01473 inhibits non-small cell lung cancer growth in a mouse model, with elevated ULBP6 levels in squamous cell carcinomas and some adenocarcinomas, leading to prioritization of four cancer types for Phase 2a trial expansion.